Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor α subunit (IL-4Rα), is the first biologic therapy approved for the treatment of moderate-to-severe atopic dermatitis (AD). This evidence concerns the gene IL4R and atopic eczema.